It was shown that HER2+ breast cancer patients who had developed resistance to trastuzumab showed significantly higher levels of HER2/ERBB2 in their ctDNA when compared to those who benefitted from the treatment [32]. This evidence concerns the gene ERBB2 and breast carcinoma.